Barclays PLC Has $13.63 Million Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Barclays PLC boosted its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 209.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 166,492 shares of the company's stock after buying an additional 112,667 shares during the period. Barclays PLC owned approximately 0.19% of HealthEquity worth $13,628,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wasatch Advisors LP grew its position in shares of HealthEquity by 6.6% during the 3rd quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company's stock worth $635,065,000 after buying an additional 483,269 shares during the period. State Street Corp boosted its stake in HealthEquity by 0.8% during the 3rd quarter. State Street Corp now owns 3,131,900 shares of the company's stock worth $256,346,000 after acquiring an additional 23,613 shares during the last quarter. Clearbridge Investments LLC grew its holdings in HealthEquity by 1.9% during the second quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company's stock valued at $204,915,000 after purchasing an additional 43,491 shares during the period. Mackenzie Financial Corp increased its stake in HealthEquity by 16.0% in the second quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company's stock valued at $203,822,000 after purchasing an additional 325,906 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in HealthEquity by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,547,402 shares of the company's stock worth $133,377,000 after purchasing an additional 115,841 shares during the period. 99.55% of the stock is owned by institutional investors.

Insider Transactions at HealthEquity

In other news, Director Stuart B. Parker sold 25,000 shares of HealthEquity stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the completion of the transaction, the director now owns 19,061 shares of the company's stock, valued at $1,843,579.92. This trade represents a 56.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert W. Selander sold 8,250 shares of the company's stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares in the company, valued at approximately $4,540,582.62. The trade was a 13.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,786 shares of company stock worth $4,140,387 in the last three months. Insiders own 2.20% of the company's stock.

Analyst Ratings Changes

HQY has been the subject of several research analyst reports. Bank of America boosted their price target on shares of HealthEquity from $100.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft boosted their target price on HealthEquity from $102.00 to $103.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. The Goldman Sachs Group began coverage on HealthEquity in a research report on Friday, November 15th. They set a "neutral" rating and a $108.00 price target on the stock. Royal Bank of Canada boosted their price objective on HealthEquity from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. Finally, Mizuho began coverage on HealthEquity in a research note on Wednesday, December 4th. They set an "outperform" rating and a $126.00 target price for the company. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $110.71.

HealthEquity Stock Down 2.6 %

HealthEquity stock traded down $2.45 during mid-day trading on Monday, reaching $93.17. The company's stock had a trading volume of 796,788 shares, compared to its average volume of 636,079. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 3.20. HealthEquity, Inc. has a 12 month low of $62.50 and a 12 month high of $105.82. The business's 50 day simple moving average is $94.28 and its 200 day simple moving average is $84.36. The company has a market capitalization of $8.07 billion, a price-to-earnings ratio of 85.48, a price-to-earnings-growth ratio of 1.10 and a beta of 0.55.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.